$099.73
Fair Price Index
The fair price of a share represents the true value of the company's share based on its financial condition and performance. Unlike the current market price, which can fluctuate depending on the mood of the market, the fair price provides us with a better understanding of whether the share is truly advantageous.
To display the fair price of a share, you need to be a member of Bulios Black.
Profile
Novo Nordisk A/S (NVO) is a Danish pharmaceutical company specializing in the development, manufacturing, and sale of medicines for the treatment of diabetes and other endocrine and metabolic disorders. The company is one of the world's leading manufacturers of insulin and insulin-related medications, which are essential for diabetes treatment. Novo Nordisk also offers other pharmaceutical products for the treatment of obesity, hemophilia, and various endocrine disorders. The company emphasizes on research and innovation in the field of diabetes and other endocrine diseases and has long been committed to fighting diabetes and obesity. Novo Nordisk A/S has extensive international operations, and its products are available in more than 170 countries. Shares of Novo Nordisk A/S (NVO) could represent an intriguing investment opportunity for those who believe in the long-term demand for diabetes and metabolic medications.
Feed
This $NVO stock news is available only to Bulios Black members.
A lot of US stocks have already regained their ATH and it looks like the rise will continue. Personally, I don't buy much anymore because I find it expensive. The exception for me is European stocks, so I will continue to overbuy $NVO.
What about you? What stocks do you still find cheap or fairly valued?
The negative news on Novo Nordisk keeps coming and the stock fell another 4% yesterday. So far I am in the red, but I still believe in the company and hope that the trend will turn around.
Do you think $NVO will turn around and start growing again this year?
Trump announced a 50% tariff on all imports from the European Union, which could be a big problem and could hurt European companies a lot. Nevertheless, I hope that the situation will calm down. So I am not changing my opinion and I still hold $ASML and $NVOshares .
What about you? Will you continue to invest in European stocks despite the current situation?
For me, it would definitely be $AMZN, $TTD and $NVO. I've been overbought these three stocks a lot lately because their price has been very low, but the fundamentals haven't changed, which I see as a great opportunity to increase my position.
As for the results, this week will probably be more interesting for me than the last one. A number of companies whose shares I hold in my portfolio will report results, and I expect bigger moves because they are growth stocks. I will be watching the results of $PLTR, $NVO, $AMD and $TTD.
Which companies' results will you be interested in?
💊 Novo Nordisk expands distribution of Wegova via telehealth. Hims & Hers shares jumped by more than 25%! Danish pharmaceutical giant Novo Nordisk $NVO is coming up with another move to accelerate sales of its weight loss drug Wegova. The drug will now also be available through telemedicine platforms such as Hims & Hers Health $HIMS, LifeMD, and including NovoCare's direct... Read more
Investors, which company in your portfolio do you understand its business best?
Each of us probably has a stock that we're really interested in, enjoy, and have gone deep into. For me, it's probably $GOOG, $ASML and $NVO - companies I've studied a lot and have a larger position in.
Novo Nordisk shares fell 9% today following news that the weight loss drug CagriSema was not as effective as expected in clinical trials. Investors may not be happy with such news, but on the other hand, this decline can be used to increase the position.
What do you think about this news? Are you buying $NVO after today's drop?
Both companies have very similar businesses and compete with each other. With $NVO, they may be at risk of tariffs that Trump might impose, and their drug may not be as popular in the US. Still, $NVO currently looks more interesting to me , which is why I've been shopping around this year. I think the stock is undervalued and the... Read more
European stocks have been relatively cheap lately, which has caught my eye, and I invested quite a bit in them last year. Currently my portfolio includes $ASML, $NVO, $MC.PA, plus Czech banks.
What European stocks do you have in your portfolio?
🗓️Klíčové market events of the week: the most important week of the month! This week is full of interesting macroeconomic data and earnings reports from key companies. Here's a summary of the highlights! 👇
🏠Monday: New home sales! Let's keep an eye on how the U.S. housing market is doing, which may indicate the health of consumers and the economy as a whole. 📊 Results before the... Read more
What do you think of today's 20% drop in $NVOstock ? Will you buy?
Novo Nordisk's shares fell sharply today following news that the weight-loss drug CagriSema achieved lower than expected efficacy in trials. I don't have $NVOstock in my portfolio, but I want to focus on this company now.
The company is doing well, but I wouldn't buy the stock as it's a pretty volatile and choppy business. You can see it just on this news alone that one drug will fail and the stock will plummet 20%. I think that's terrible.
In the past month alone, $NVOstock is down more than 11%, and according to the Bulios Fair Price Index, the stock is currently slightly undervalued. Recently @edin_medinmentioned this stock , and frankly I'm starting to think about buying it too. If $NVO stock were to drop another 5, 6%, I would buy.
A month ago I was buying cheap $NVDA and now I'd rather save my money for the next drop.